Matthew's life doesn’t look like what he imagined when he was an active Cajun boy. Once diagnosed at age 11 with Friedreich’s ataxia, he threw himself into books, writing, and studies, achieving a bachelor’s degree in English and a master’s degree in mental health counseling. Writing a column at Friedreich’s Ataxia News and serving as the associate director of columns for its parent company BioNews is a perfect combination of his two degrees. He notes life’s small, often overlooked successes in his column. In progressive disability, Matt tries to notice his little victories, hoping that others notice their own ... or something like that.After Skyclarys, a new odyssey begins with Friedreich’s ataxia
The recent approval of Skyclarys (omaveloxolone), the first treatment for Friedreich’s ataxia (FA), is game-changing. But I’m frustrated that there’s still a long journey ahead for me. When this drug was approved Feb. 28, I celebrated in a column posted minutes after the announcement. A few…